ETON - CIK 0001710340
Eton Pharmaceuticals, Inc. (ETON) reported net income of -$4.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$4.60M | -20.4% |
| FY 2024 | -$3.82M | -308.4% |
| FY 2023 | -$936.00K | +89.6% |
| FY 2022 | -$9.02M | -361.4% |
| FY 2021 | -$1.96M | +93.0% |
| FY 2020 | -$27.97M | -52.7% |
| FY 2019 | -$18.32M | -43.8% |
| FY 2018 | -$12.74M | - |
Eton Pharmaceuticals, Inc. (ETON) reported net income of -$4.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, Eton Pharmaceuticals, Inc.'s net income grew from -$12.74M to -$4.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.